Vitamin D Supplementation and Clinical Outcomes in Severe COVID-19 Patients—Randomized Controlled Trial

Nutrients, Journal Year: 2023, Volume and Issue: 15(5), P. 1234 - 1234

Published: Feb. 28, 2023

COVID-19 symptoms vary from asymptomatic cases to moderate and severe illness with patients needing hospitalization intensive care treatment. Vitamin D is associated severity of viral infections has an immune-modulatory effect in immune response. Observational studies showed a negative association low vitamin levels mortality outcomes. In this study, we aimed determine whether daily supplementation during unit (ICU) stay affects clinically relevant Patients disease need respiratory support admitted the ICU were eligible for inclusion. randomized into one two groups: intervention group received control did not receive supplementation. total, 155 randomized: 78 77 group. There was no statistically significant difference number days spent on support, although trial underpowered main outcome. any secondary outcomes analyzed between groups. Our study suggests benefit

Language: Английский

---

Putative Role of Vitamin D for COVID-19 Vaccination

International Journal of Molecular Sciences, Journal Year: 2021, Volume and Issue: 22(16), P. 8988 - 8988

Published: Aug. 20, 2021

Severe acute respiratory syndrome coronavirus 2 is a new, highly pathogenic virus that has recently elicited global pandemic called the 2019 disease (COVID-19). COVID-19 characterized by significant immune dysfunction, which caused strong but unregulated innate immunity with depressed adaptive immunity. Reduced and delayed responses to interferons (IFN-I/IFN-III) can increase synthesis of proinflammatory cytokines extensive cell infiltration into airways, leading pulmonary disease. The development effective treatments for severe patients relies on our knowledge pathophysiological components this imbalanced response. Strategies address response factors will be essential. Significant efforts are currently underway develop vaccines against SARS-CoV-2. vaccines, such as inactivated DNA, mRNA, protein subunit have already been applied in clinical use. Various display different levels effectiveness, it important continue optimize update their composition order effectiveness. However, due continuous emergence variant viruses, improving general public may also effectiveness vaccines. Many observational studies demonstrated serum vitamin D inversely correlated incidence or severity COVID-19. Extensive evidence shown supplementation could vital mitigating progression reduce its severity. Vitamin defends SARS-CoV-2 through complex mechanism interactions between modulation reactions, ACE2 expression, inhibition renin-angiotensin system (RAS). remains unclear whether Vit-D plays an role Based analysis molecular involved, we speculated vit-D, via various signaling pathways, complementary vaccine efficacy.

Language: Английский

---

Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D

Biomedicine & Pharmacotherapy, Journal Year: 2022, Volume and Issue: 150, P. 112965 - 112965

Published: April 14, 2022

Main cause of severe illness and death in COVID-19 patients appears to be an excessive but ineffectual inflammatory immune response that may acute respiratory distress syndrome (ARDS). Vitamin D favour anti-inflammatory environment improve cytotoxic against some infectious diseases. A multicenter, single-blind, prospective, randomized clinical trial was approved with pneumonia levels 25-hydroxyvitamin (25(OH)D) 14.8 ng/ml (SD: 6.18) test antiviral efficacy, tolerance safety 10,000 IU/day cholecalciferol (vitamin

Language: Английский

---

Consensus and Controversial Aspects of Vitamin D and COVID-19

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2022, Volume and Issue: 108(5), P. 1034 - 1042

Published: Dec. 8, 2022

Abstract Objective This work aims to review and discuss controversial topics in the field of vitamin D, SARS-CoV-2 infection, COVID-19. Methods The International Conferences “Controversies Vitamin D” are a series workshops that started 2017 featuring international experts leaders D research clinical practice. fifth annual conference was held Stresa, Italy, September 15 18, 2021. Evidence Before event, participants reviewed available studies on their assigned topic, drafted related abstract, presented findings at time conference. Relevant literature became since also discussed within panel updated accordingly. Consensus abstracts had been merged prepare preliminary document. After presentations, in-depth discussions open sessions led consensus. document subsequently modified according up-to-date inclusion. Conclusions There is quite consistent evidence for an association between low 25 OH (25(OH)D) levels poor COVID-19 outcomes, despite heterogeneous publications variable quality. However, status patients might reflect reverse causality. supplementation have positive role prevention. supporting beneficial effect treatment decreasing risk complications conflicting. Conclusive statements regarding this context await high-quality, randomized controlled trials.

Language: Английский

---

The effect of macronutrient and micronutrient supplements on COVID-19: an umbrella review

Journal of Health Population and Nutrition, Journal Year: 2024, Volume and Issue: 43(1)

Published: Jan. 29, 2024

Abstract Background and aims A healthy diet play an important role in the prevention even treatment of various diseases. Proper nutrition plays boosting immune system. These include consumption macronutrients such as proteins, lipids, carbohydrates, also micronutrients including vitamins. Here, we aimed to systematically review effects on COVID-19. Methods We searched databases PubMed, Scopus, Embase, Web Science December 23, 2023. The records were downloaded into EndNote file, duplicates removed, studies underwent a two-phase screening process based their title/abstracts full texts. included articles screened inclusion exclusion criteria. English systematic reviews meta-analyses that concurred with aim our study. selected assessed by Cochrane's Risk Bias Systematic Reviews for quality check. data eligible extracted pre-designed word table used qualitative synthesis. Results total 28 this Most have shown are effective morbidity mortality controlling viral respiratory infections COVID-19 but some sometimes not severity. On other hand, calcifediol was far most successful agent reducing intensive care needs between studies. Conclusion Individuals without malnutrition had reduced risk SARS-CoV-2 infection severe disease. administration Vitamin D is patients. Patients vitamin deficiency more prone experience infection, they at higher morbidities mortality. Other A, B, Zinc showed benefits patients C no efficacy management intravenous form or high doses.

Language: Английский

---

Beneficial Effect of Short-Term Supplementation of High Dose of Vitamin D3 in Hospitalized Patients With COVID-19: A Multicenter, Single-Blinded, Prospective Randomized Pilot Clinical Trial

Frontiers in Pharmacology, Journal Year: 2022, Volume and Issue: 13

Published: July 4, 2022

There is now sufficient evidence to support that vitamin D deficiency may predispose SARS-CoV-2 infection and increase COVID-19 severity mortality. It has been suggested 3 supplementation be used prophylactically as an affordable safe strategy could added the existing standard treatment. This multicenter, single-blinded, prospective randomized pilot clinical trial aimed evaluate safety, tolerability, effectiveness of 10,000 IU/day in comparison with 2000 cholecalciferol for 14 days reduce duration 85 hospitalized individuals. The median age participants was 65 years (Interquartile range (IQR): 53–74), most them (71%) were men mean baseline 25-hydroxyvitamin (25(OH)D) serum 15 ng/ml (standard deviation (SD):6). After supplementation, 25(OH)D levels significantly increased group who received 10,000IU/day ( p < 0.0001) n = 44) 2,000IU/day 41), especially overweight obese participants, higher dose well tolerated. A fraction individuals our cohort (10/85) developed acute respiratory distress syndrome (ARDS). length hospital stay these patients ARDS different assigned 4; 7 days; IQR: 4–13) 6; 27 12–45) 0.04). Moreover, inspired oxygen reduced 7.6-fold high 0.049). In terms blood parameters, we did not identify overall significant improvements, although platelet count showed a modest but difference those supplemented 0.0492). conclusion, administration association care during hospitalization safe, tolerable, beneficial, thereby helping improve prognosis recovery process.

Language: Английский

---

Insufficient evidence for vitamin D use in COVID‐19: A rapid systematic review

International Journal of Clinical Practice, Journal Year: 2021, Volume and Issue: 75(11)

Published: July 26, 2021

Vitamin D deficiency has been linked to the increased severity of numerous viral infections.

Language: Английский

---

High-dose vitamin D substitution in patients with COVID-19: study protocol for a randomized, double-blind, placebo-controlled, multi-center study—VitCov Trial

Trials, Journal Year: 2022, Volume and Issue: 23(1)

Published: Feb. 4, 2022

Abstract Background The coronavirus disease 19 (COVID-19) pandemic has caused millions of deaths, and new treatments are urgently needed. Factors associated with a worse COVID-19 prognosis include old age (> 65 years), ethnicity, male sex, obesity, people comorbidities. Furthermore, vitamin D deficiency was reported as predictor poor in patients acute respiratory failure due to COVID-19. According recent clinical case series, is modifiable risk factor, which the prospect reducing hospital stay, intensive care, fatal outcomes. Vitamin potent immunomodulatory properties, its supplementation might improve important outcomes critically ill D-deficient patients. Despite evidence that supports an association between severity, there uncertainty about direct link. Therefore, aim trial assess if high-dose therapeutic effect Methods As design, randomized, placebo-controlled, double-blind, multi-center approach chosen compare high single dose (140,000 IU) followed by treatment usual (TAU) (VitD + TAU) only (placebo deficiency. Discussion substitution should be investigated for efficacy safety. study test hypothesis suffering from treated under standardized conditions will recover faster when additionally supplementation. Latest studies suggest highly recommended positively influence course disease. With this randomized controlled trial, contribution guidelines shall made. Trial registration ClinicalTrials.gov NCT04525820 SNCTP 2020-01401

Language: Английский

---

Susceptibility to COVID-19 Nutrition Misinformation and Eating Behavior Change during Lockdowns: An International Web-Based Survey

Nutrients, Journal Year: 2023, Volume and Issue: 15(2), P. 451 - 451

Published: Jan. 14, 2023

To understand the susceptibility to nutrition-health misinformation related preventing, treating, or mitigating risk of COVID-19 during initial lockdowns around world, present international web-based survey study (15 April-15 May 2020) gauged participants' (

Language: Английский

---

Effect of vitamin D supplementation versus placebo on recovery delay among COVID-19 Tunisian patients: a randomized-controlled clinical trial

Trials, Journal Year: 2023, Volume and Issue: 24(1)

Published: Feb. 20, 2023

Abstract Introduction The present study aimed to determine the impact of vitamin D supplementation (VDs) on recovery delay among COVID-19 patients. Methods We performed a randomized controlled clinical trial at national containment center in Monastir (Tunisia), from May August 2020. Simple randomization was done 1:1 allocation ratio. included patients aged more than 18 years who had confirmed reverse transcription-polymerase chain reaction (RT-PCR) and remained positive 14th day. intervention group received VDs (200,000 IU/1 ml cholecalciferol); control placebo treatment (physiological saline (1 ml)). measured cycle threshold (Ct) values RT-PCR for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). log-rank test hazard ratios (HR) were calculated. Results A total 117 enrolled. mean age 42.7 (SD 14). Males represented 55.6%. median duration viral RNA conversion 37 days (95% confidence interval (CI): 29–45.50) 28 CI: 23–39) ( p =0.010). HR 1.58 1.09–2.29, =0.015). Ct revealed stable trend over time both groups. Conclusion not associated with shortened when given whom Trial registration This approved by Human Subjects Protection Tunisia (TN2020-NAT-INS-40) April 28, 2020, ClinicalTrial.gov 12, 2021 approval number ClinicalTrials.gov ID: NCT04883203 .

Language: Английский

---